Karen L. Smith insider trades

Open-market stock purchases and sales by Karen L. Smith, Director at Context Therapeutics Inc, from SEC Form 4 filings since May 11, 2015.

Track record: 100% of 4 scored buys are up 5% or more since purchase, averaging +73%.

Recent trades

DateStockTradeValue
Jun 24, 2026CNTX Context Therapeutics IncBought (not open market)—
Mar 31, 2026SKYE Skye Bioscience, IncBought (not open market)—
Feb 6, 2026SKYE Skye Bioscience, IncBought (not open market)—

Companies traded

  • CNTX Context Therapeutics Inc: other filings, last Jun 24, 2026
  • SKYE Skye Bioscience, Inc: other filings, last Mar 31, 2026
  • SGMO Sangamo Therapeutics, Inc: other filings, last Jun 12, 2025
  • AUPH Aurinia Pharmaceuticals Inc: 1 sale, last Nov 21, 2024
  • TALS Talaris Therapeutics, Inc: other filings, last Jun 13, 2023
  • QNCX Quince Therapeutics, Inc: other filings, last Feb 1, 2023
  • ATRS Antares Pharma, Inc: other filings, last May 24, 2022
  • CRTX Cortexyme, Inc: other filings, last May 23, 2022
  • XLRN Acceleron Pharma Inc: 6 sales, last Nov 19, 2021
  • EBS Emergent BioSolutions Inc: other filings, last May 7, 2021
  • JAZZ Jazz Pharmaceuticals plc: 4 buys, last Mar 5, 2018
  • SCMP Sucampo Pharmaceuticals, Inc: other filings, last Feb 13, 2018

Get free alerts when Karen L. Smith files a new trade →